journal article·2021-01-05Open access

Recent Advances in Nanoparticle-Mediated Treatment of Inflammatory Bowel Diseases

Andreea Nedelcu, Ofelia Mosteanu, Teodora Pop, Teodora Mocan, Lucian Mocan

Applied Sciences· Volume 11· Issue 1

Abstract

There have been continuous advances in nanoscience since the beginning of the 21st century, and the emerging field of computational nanomedicine, the development of nanomaterial-based sensors or the prominent biomedical engineering applications should be mentioned. Intestinal disorders causing prolonged inflammation of the digestive tract, largely known as inflammatory bowel disease (IBD), include Crohn’s disease (CD) and ulcerative colitis (UC), have seen a significant increase in incidence rates. Nanoparticle-based approaches to locally target therapy could help regulate immune responses and act as an anti-inflammatory in individual patients diagnosed with IBD. The results of the paper emphasize the major role that nanoparticle-mediated drug delivery has in IBD treatment, giving IBD patients in remission the chance for a more effective drug therapy with a decreased medication load.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inflammatory Bowel Disease · Microscopic Colitis · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

3rd Surgery Clinic, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400008 Cluj-Napoca, Romania

3rd Medical Clinic, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400162 Cluj-Napoca, Romania

Physiology Department, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania

Funding

University of Medicine and Pharmacy Cluj-Napoca , Romania

References (41)

Show source-provided references
1. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease10.3748/wjg.v21.i40.11343 ↗
2. Nanotechnology in the treatment of inflammatory bowel diseases10.1016/j.crohns.2014.02.024 ↗
3. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease10.1016/j.biomaterials.2018.09.005 ↗
4. Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis10.2147/DDDT.S170676 ↗
5. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model10.1016/j.ejpb.2008.12.013 ↗
6. Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model10.1208/s12249-019-1453-5 ↗
7. Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model
8. Oral nanotherapeutics: Effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis10.1007/s00535-013-0836-8 ↗
9. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis10.1016/j.ijpharm.2013.05.017 ↗
10. A molecular targeted immunotherapeutic strategy for ulcerative colitis via dual-targeting nanoparticles delivering miR-146b to intestinal macrophages10.1093/ecco-jcc/jjy181 ↗
11. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice10.1053/j.gastro.2014.01.056 ↗
12. Fab’-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis10.1016/j.jconrel.2014.04.046 ↗
13. Glycyrrhizic acid-loaded pH-sensitive poly-(lactic-co-glycolic acid) nanoparticles for the amelioration of inflammatory bowel disease10.2217/nnm-2018-0415 ↗
14. Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery10.1016/j.ijpharm.2006.01.032 ↗
15. Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies10.1016/j.ijpharm.2012.07.017 ↗
16. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases10.1016/j.jconrel.2014.03.039 ↗
17. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease10.1016/j.ijpharm.2014.07.009 ↗
18. Protective efficacy of ursodeoxycholic acid nanoparticles in animal model of inflammatory bowel disease10.3109/02652048.2014.918666 ↗
19. Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon10.1016/j.colsurfb.2014.09.026 ↗
20. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy
21. Surfactant-dependence of nanoparticle treatment in murine experimental colitis10.1016/j.jconrel.2013.07.031 ↗
22. Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly (D, L-lactide-co-glycolide) nanospheres for inflammatory bowel disease10.1016/j.biomaterials.2010.09.034 ↗
23. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats10.1124/jpet.105.088146 ↗
24. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease
25. A Proresolving Peptide Nanotherapy for Site-Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota10.1002/advs.201900610 ↗
26. Nanoparticle-based clodronate delivery mitigates murine experimental colitis10.1016/j.jconrel.2012.03.004 ↗
27. Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis10.1111/j.1472-8206.2011.00966.x ↗
28. Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis10.1016/j.jconrel.2014.05.046 ↗
29. Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model10.1016/j.ejps.2010.01.013 ↗
30. Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats
31. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model10.1053/j.gastro.2009.11.003 ↗
32. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis10.1002/ibd.21469 ↗
33. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis10.1016/j.biomaterials.2008.08.009 ↗
34. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease10.1016/j.jconrel.2007.08.008 ↗
35. Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression10.1038/s41598-019-46671-1 ↗
36. Oral Targeted Delivery by Nanoparticles Enhances Efficacy of an Hsp90 Inhibitor by Reducing Systemic Exposure in Murine Models of Colitis and Colitis-Associated Cancer10.1093/ecco-jcc/jjz113 ↗
37. Oral administration of colitis tissue-accumulating porous nanoparticles for ulcerative colitis therapy10.1016/j.ijpharm.2018.12.046 ↗
38. Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis10.1007/s10620-006-9738-4 ↗
39. Effects of particle size and binding affinity for small interfering RNA on the cellular processing, intestinal permeation and anti-inflammatory efficacy of polymeric nanoparticles10.1002/jgm.2866 ↗
40. Embelin lipid nanospheres for enhanced treatment of ulcerative colitis–Preparation, characterization and in vivo evaluation10.1016/j.ejps.2015.05.003 ↗
41. pH-sensitive nanoparticles of curcumin–celecoxib combination: Evaluating drug synergy in ulcerative colitis model10.1002/jps.23828 ↗